| Another year of the obtuse, odd and obscure
Throughout 2007, Telescope has brought you the sort of news that, quite frankly, doesn't quite fit into most people's definition of news. Take, for instance, this newspaper correction gleaned from the pages of the New York Times -- proving definitively that not only does that august journal publish all the jokes that are fit to print, but it strives to get them right, too: "Because of an editing error, an obituary on Sunday about Sid Raymond, a comic actor, rendered one of his jokes incorrectly. It was about a son who sends a prostitute to his widowed father, still a self-proclaimed ladies' man in his 90s. The prostitute tells the father that she is his birthday present and promises to give him 'super sex'... . The father replies, 'I'll take the soup.' " There is plenty more where that came from.
This Crisis Demands a Reappraisal of Who We Are and What Progress ...
Last year Joshuah Stolaroff, who has written a PhD on the subject, sent me some provisional costings, of £256-£458 per tonne of carbon. This makes the capture of CO2 from the air roughly three times as expensive as the British government's costings for building wind turbines, twice as expensive as nuclear power, slightly cheaper than tidal power and eight times cheaper than rooftop solar panels in the UK. But I suspect his figures are too low, as they suggest this method is cheaper than catching CO2 from purpose-built power stations, which cannot be true. The Kyoto protocol, whose replacement the Bali meeting will discuss, has failed. Since it was signed, there has been an acceleration in global emissions: the rate of CO2 production exceeds the IPCC's worst case and is now growing faster than at any time since the beginning of the industrial revolution.
PrecisionRx Specialty Solutions Chosen as a Distributor for Letairis
INDIANAPOLIS, Oct. 31 /PRNewswire/ -- WellPoint, Inc., (NYSE: WLP) , the nation's largest health benefits company, today announced that its wholly owned specialty pharmacy, PrecisionRx Specialty Solutions, has been selected by Gilead Sciences as one of eight pharmacies in the United States to participate in the limited distribution program for Letairis, an oral drug that treats a potentially lethal form of pulmonary arterial hypertension (PAH). PrecisionRx Specialty Solutions was chosen as a distributor for the drug because of its capacity to provide "high touch" specialized support for people with complex, chronic diseases. "We were delighted with Gilead's decision to include PrecisionRx Specialty Solutions in their limited distribution channel," said Recie Bomar, vice president for specialty pharmacy.
|
